PNCA.NS
Latest Trade
115.80INRChange
0.85(+0.74%)Volume
4,001Today's Range
-
117.0052 Week Range
-
215.95As of on the National Stock Exchange of India ∙ Minimum 15 minute delay
Previous Close | 114.95 |
|---|---|
Open | 115.90 |
Volume | 4,001 |
3M AVG Volume | 0.63 |
Today's High | 117.00 |
Today's Low | 115.10 |
52 Week High | 215.95 |
52 Week Low | 112.50 |
Shares Out (MIL) | 61.30 |
Market Cap (MIL) | 6,982.59 |
Forward P/E | -- |
Dividend (Yield %) | -- |
India's Panacea Biotec Sept-Qtr Consol Net Loss After Tax Widens
India's Panacea Biotec June-Qtr Consol Net Loss After Tax Narrows
Panacea Biotec Gets Azacitidine USFDA Approval For U.S. Market
Panacea Biotec Limited is a health management company. The Company's principal business activity is the manufacture of allopathic pharmaceuticals preparations. The Company's segments include Vaccines, Formulations, Research and Development; Healthcare and Real estate activities. Its Vaccines, Formulations and Research & Development segments are engaged in the business of research, development, manufacture and marketing of vaccines and branded pharmaceutical formulations. It has products for various segments, which include pediatric vaccines, pain management, diabetes management and organ transplantation. Its Healthcare segment is engaged in business of operating and maintaining hospitals. Its Real estate activities segment is engaged in the business of acquisition, construction and development of housing and commercial real estate projects. The Company's product portfolio includes prescription products in therapeutic areas, such as oncology, and nephrology and transplant management.
Industry
Biotechnology & Drugs
Contact Info
B-1 Extn / G-3
Mathura Road, Mohan Co-opIndlEstate
+91.11.41679000
https://www.panacea-biotec.com/Executive Leadership
Soshil Kumar Jain
Whole-Time Chairman of the Board
Devender Gupta
Chief Financial Officer
Vinod Goel
Compliance Officer, Company Secretary, General Manager - Legal
Rajesh Jain
Managing Director, Executive Director
Sandeep Jain
Joint Managing Director, Executive Director
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | -- |
Price To Book (MRQ) | 2.43 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 278.21 |
LT Debt To Equity (MRQ) | 227.97 |
Return on Investment (TTM) | -- |
Return on Equity (TTM) | -- |
* GETS ESTABLISHMENT INSPECTION REPORT INDICATING FORMAL CLOSURE OF INSPECTION AT PHARMACEUTICAL FORMULATION FACILITY AT MALPUR
* MD RAVINDER JAIN PASSES AWAY Source text - http://bit.ly/2sLxQk2 Further company coverage:
* DEC QUARTER NET LOSS 97.1 MILLION RUPEES VERSUS LOSS 254.2 MILLION RUPEES YEAR AGO
* SAYS SIGNED TWO LONG AGREEMENTS WITH SERUM INSTITUTE OF INDIA AND BILTHOVAN BIOLOGICALS B V Source text: http://bit.ly/2ESdxT8 Further company coverage:
* SAYS U.S. FDA ACCEPTS CO'S ANDA FOR PACLITAXEL PROTEIN BOUND PARTICLES Source text: http://bit.ly/2BnVN02 Further company coverage:
* Sept quarter net loss 56.3 million rupees versus loss 49.5 million rupees year ago
* Co signs deal with India's technology development board for financial assistance of 289.9 million rupees
* Sept quarter net loss 56.3 million rupees versus loss 49.5 million rupees year ago
* Panacea Biotec - gets certificate of GMP compliance from state service of Ukraine on Medicines and Drug Control
* June quarter net loss 479.9 million rupees versus loss 204.9 million rupees year ago
* Says expands collaboration with Apotex to launch prasugrel in US
* Entered into joint collaboration for development, license, among others for 7 complex generic pharmaceutical products with Bionpharma Inc Source text for Eikon: Further company coverage:
Indian healthcare services provider Narayana Hrudayalaya Ltd said it would buy NewRise Healthcare Private Ltd from Panacea Biotec Ltd for an enterprise value of 1.80 billion rupees ($27.87 million).
* Says introduces fully liquid hexavalent combination vaccine easysixtm for six preventable diseases Source text for Eikon: Further company coverage:
* Panacea Biotec clarifies on news item "Narayana Hrudayalaya in advanced talks to buy Panacea Biotec's Gurgaon hospital."
* Dec quarter net loss 292.5 million rupees versus loss 173.8 million rupees year ago
* Panacea Biotec Ltd says ANDA approval for us market and lta & award from un agencies for supply of pentavalent vaccine (easyfive-TT)
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.